Literature DB >> 1695528

Comparison of immunocytochemical and biochemical assays for estrogen receptor in fine needle aspirates and histologic sections from breast carcinomas.

R L Katz1, S Patel, N Sneige, H A Fritsche, G N Hortobagyi, F C Ames, T Brooks, N G Ordonez.   

Abstract

An immunocytochemical assay using a monoclonal antibody specific for estrogen receptor (ER-ICA) was performed on needle aspirates and on histologic sections (mastectomy and biopsy specimens) from 55 patients with breast cancer. A total of 82 ER-ICAs were performed, with matched cytologic and histologic specimens in 27 patients, cytology alone in 15, and histology alone in 13. ER-ICA results were described by a histochemical score (H score) based on intensity-weighted percentages of staining cells. The H scores were compared with results of sucrose density gradient (SDG) analysis of histologic specimens (mastectomy, resection, or biopsy). An H score greater than or equal to 10 and an SDG value greater than or equal to 10 fmol/mg protein were considered positive. The sensitivity of cytologic ER-ICA was 94%, the specificity 100%. The sensitivity of histologic ER-ICA was 67%, the specificity 90%. Correlating cytologic H score with Black's nuclear grade showed that grade 1 (the most anaplastic) carcinomas demonstrated the lowest H scores (mean, 7.3 +/- 29.8), whereas the highest H scores were noted in grade 3 tumors (mean, 150.0 +/- 88.1). Both SDG and ER-ICA showed ER values to be lower in premenopausal than postmenopausal women. There was no correlation between H score and presence of axillary nodal metastases or tumor size. An overall good correlation was demonstrated between immunohistochemical methods and biochemical analysis.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1695528     DOI: 10.1007/bf01806356

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  24 in total

1.  Nuclear structure in cancer tissues.

Authors:  M M BLACK; F D SPEER
Journal:  Surg Gynecol Obstet       Date:  1957-07

2.  Correlation of immunocytochemically demonstrated estrogen receptor distribution and histopathologic features in primary breast cancer.

Authors:  U Berger; P Wilson; R A McClelland; J Davidson; R C Coombes
Journal:  Hum Pathol       Date:  1987-12       Impact factor: 3.466

3.  Monoclonal antibody staining and impact of surgical technique on the identification and quantitation of steroid receptors in human breast cancer.

Authors:  J Butler; A Hieshima; D Bernstein; S Huang; D State
Journal:  Am J Surg       Date:  1987-07       Impact factor: 2.565

4.  Immunocytochemical assay for estrogen receptor: relationship to outcome of therapy in patients with advanced breast cancer.

Authors:  R A McClelland; U Berger; L S Miller; T J Powles; E V Jensen; R C Coombes
Journal:  Cancer Res       Date:  1986-08       Impact factor: 12.701

5.  Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies.

Authors:  K S McCarty; L S Miller; E B Cox; J Konrath; K S McCarty
Journal:  Arch Pathol Lab Med       Date:  1985-08       Impact factor: 5.534

6.  Estrogen receptor analysis on biopsies and fine-needle aspirates from human breast carcinoma. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies.

Authors:  A Reiner; J Spona; G Reiner; M Schemper; R Kolb; W Kwasny; R Függer; R Jakesz; J H Holzner
Journal:  Am J Pathol       Date:  1986-12       Impact factor: 4.307

7.  Evaluation of estrogen receptors by immunocytochemistry on fine-needle aspiration biopsy specimens from breast tumors.

Authors:  J Weintraub; D Weintraub; M Redard; P Vassilakos
Journal:  Cancer       Date:  1987-09-15       Impact factor: 6.860

8.  Correlation of estrogen receptor and pathologic characteristics of invasive breast cancer.

Authors:  E R Fisher; C K Redmond; H Liu; H Rockette; B Fisher
Journal:  Cancer       Date:  1980-01-15       Impact factor: 6.860

9.  Oestrogen receptor activity in breast cancer detected at a prevalence screening examination.

Authors:  M M Roberts; R A Hawkins; F E Alexander; T J Anderson; R J Steele
Journal:  Breast Cancer Res Treat       Date:  1987-12       Impact factor: 4.872

10.  Comparison of immunocytochemical and steroid-binding assays for estrogen receptor in human breast tumors.

Authors:  W J King; E R DeSombre; E V Jensen; G L Greene
Journal:  Cancer Res       Date:  1985-01       Impact factor: 12.701

View more
  8 in total

1.  A profile of prognostic and molecular factors in European and Māori breast cancer patients.

Authors:  Gabi U Dachs; Maiko Kano; Ekaterina Volkova; Helen R Morrin; Valerie C L Davey; Gavin C Harris; Michelle Cheale; Christopher Frampton; Margaret J Currie; J Elisabeth Wells; Bridget A Robinson
Journal:  BMC Cancer       Date:  2010-10-10       Impact factor: 4.430

2.  Estrogen receptors in 699 primary breast cancers: a comparison of immunohistochemical and biochemical methods.

Authors:  A Molino; R Micciolo; M Turazza; F Bonetti; Q Piubello; A Corgnati; L Sperotto; G Martignoni; A Bonetti; R Nortilli
Journal:  Breast Cancer Res Treat       Date:  1995-06       Impact factor: 4.872

3.  Fine-needle aspiration technique for the concurrent immunocytochemical evaluation of multiple biologic parameters in primary breast carcinoma.

Authors:  C Bozzetti; R Nizzoli; N Naldi; L Manotti; L Savoldi; R Camisa; A Guazzi; G Cocconi
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

4.  Tetraspanin CD151 is a novel prognostic marker in poor outcome endometrial cancer.

Authors:  M A Voss; N Gordon; S Maloney; R Ganesan; L Ludeman; K McCarthy; R Gornall; G Schaller; W Wei; F Berditchevski; S Sundar
Journal:  Br J Cancer       Date:  2011-04-19       Impact factor: 7.640

5.  Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.

Authors:  Matthew J Ellis; Yu Tao; Jingqin Luo; Roger A'Hern; Dean B Evans; Ajay S Bhatnagar; Hilary A Chaudri Ross; Alexander von Kameke; William R Miller; Ian Smith; Wolfgang Eiermann; Mitch Dowsett
Journal:  J Natl Cancer Inst       Date:  2008-09-23       Impact factor: 13.506

6.  Variation of hormonal receptor, pS2, c-erbB-2 and GSTpi contents in breast carcinomas under tamoxifen: a study of 74 cases.

Authors:  I Soubeyran; N Quénel; L Mauriac; M Durand; F Bonichon
Journal:  Br J Cancer       Date:  1996-03       Impact factor: 7.640

7.  pS2 protein: a marker improving prediction of response to neoadjuvant tamoxifen in post-menopausal breast cancer patients.

Authors:  I Soubeyran; N Quénel; J M Coindre; F Bonichon; M Durand; J Wafflart; L Mauriac
Journal:  Br J Cancer       Date:  1996-10       Impact factor: 7.640

8.  Staging laparoscopy and peritoneal cytology in patients with early stage gastric adenocarcinoma.

Authors:  Casey J Allen; Alisa N Blumenthaler; Prajnan Das; Bruce D Minsky; Mariela Blum; Sinchita Roy-Chowdhuri; Jaffer A Ajani; Naruhiko Ikoma; Paul F Mansfield; Brian D Badgwell
Journal:  World J Surg Oncol       Date:  2020-02-17       Impact factor: 2.754

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.